BetaLife develops regenerative medicine solutions for diabetes using next-generation human induced pluripotent stem cell (hiPSC) technology. The company focuses on generating functional, clinical-grade pancreatic islet cells for cell replacement therapy. This platform aims to provide off-the-shelf cell products to improve outcomes for diabetes patients.
Funding
$800K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for diabetes, such as insulin injections and oral medications, often fail to fully address the underlying pancreatic beta cell dysfunction and carry risks of complications like hypoglycemia. The limited availability of donor islets for transplantation and the need for immunosuppression further restrict effective long-term solutions.
Solution
BetaLife is developing cell replacement therapies for diabetes using clinical-grade human induced pluripotent stem cells (iPSCs). Their technology enables the generation of functional pancreatic islet cells from iPSCs, offering a scalable and sustainable source for cell transplantation. These iPSC-derived islet cells aim to restore insulin production in patients with type 1 and type 2 diabetes, reducing or eliminating the need for exogenous insulin. BetaLife also provides personalized iPSC banking services, allowing individuals to preserve their own stem cells for potential future therapeutic applications and research contributions.
Target Audience
BetaLife serves institutions, including research organizations and hospitals, seeking iPSCs and differentiated cell products for research and therapeutic development, as well as individuals interested in personalized iPSC banking for potential future regenerative medicine applications.
Features
- Manufacturing of clinical-grade human iPSCs and iPSC-derived islet cells
- Generation of iPSCs from healthy and diabetic individuals of Asian ethnicities
- Production of pancreatic cells at various developmental stages (definitive endoderm, pancreatic endoderm, endocrine progenitors, and fully-differentiated islet cells)
- Custom iPSC generation and differentiation services tailored to specific research projects
- cGMP-compliant iPSC generation for clinical applications (available in 2023)
- Personalized iPSC banking for future cell-based therapies and regenerative medicine research